|
Real-time Estimate
Cboe BZX
10:56:02 2026-10-30 am EDT
|
5-day change | 1st Jan Change | ||
| 915.36 USD | +11.80% |
|
+13.01% | +17.86% |
| 10:21am | Regeneron Pharma 3Q Sales Climb on Dupixent Growth | DJ |
| 10:06am | Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| Market Cap | 81.76B 73.23B 67.56B 61.14B 114B 7,786B 116B 806B 322B 4,075B 307B 300B 12,905B | P/E 2026 * |
16.9x | P/E 2027 * | 15.7x |
|---|---|---|---|---|---|
| Enterprise Value | 74.16B 66.42B 61.28B 55.45B 104B 7,062B 105B 731B 292B 3,696B 278B 272B 11,705B | EV / Sales 2026 * |
4.21x | EV / Sales 2027 * | 3.81x |
| Free-Float |
71.06% | Yield 2026 * |
0.48% | Yield 2027 * | 0.52% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| REGN | Delayed | |
CBOE
| REGN | Real-time | |
|
Tradegate
| RGO | Real-time | |
|
Mexican S.E.
| REGN * | End-of-day quote | |
|
Boerse Muenchen
| RGO | Real-time | |
|
Xetra
| RGO | End-of-day quote | |
|
Börse Stuttgart
| RGO | Delayed | |
|
London S.E.
| 0R2M | Delayed | |
|
Borsa Italiana
| 1REGN | End-of-day quote | |
|
Deutsche Boerse AG
| RGO | Delayed | |
|
Wiener Boerse
| REGN | End-of-day quote | |
|
Lima
| REGNUS | End-of-day quote |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +11.30% | ||
| 1 week | +14.29% | ||
| Current month | +21.33% | ||
| 1 month | +21.33% | ||
| 3 months | +24.61% | ||
| 6 months | +30.12% | ||
| Current year | +19.20% |
| 1 week | 796.61 |  | 935.35 |
| 1 month | 722.02 | | 935.35 |
| Current year | 591.52 | | 935.35 |
| 1 year | 591.52 | | 935.35 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 2000-12-31 | |
| Chief Executive Officer | 73 | 1988-01-07 | |
| Director of Finance/CFO | 55 | 2024-02-04 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 2023-06-08 | |
Joseph Goldstein
BRD | Director/Board Member | 85 | 1991-05-31 |
George Sing
BRD | Director/Board Member | 76 | 1988-01-07 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/14/26 | Sell | Chief Technology Officer | -4,147 | 0.0041% | ||
| 9/3/26 | Sell | Executive/Senior Manager | -1,131 | 0.0011% | ||
| 9/2/26 | Exercice | Director | 1,200 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.55% | +14.29% | +40.67% | +18.31% | 81.76B | |
| +3.80% | +11.85% | +68.66% | +151.78% | 1,224B | |
| +0.47% | +5.25% | +46.87% | +88.84% | 662B | |
| +0.91% | +3.03% | +28.97% | +107.41% | 514B | |
| -0.16% | +2.84% | +53.61% | +66.60% | 388B | |
| +0.81% | +2.36% | +72.35% | +44.82% | 361B | |
| +1.01% | +4.84% | +35.72% | +58.57% | 302B | |
| +5.68% | +7.99% | +10.38% | +35.53% | 271B | |
| +1.55% | +7.02% | +60.99% | +78.61% | 249B | |
| +2.70% | +10.35% | +45.38% | +121.41% | 205B | |
| Average | +2.86% | +2.33% | +46.36% | +77.19% | 425.86B | |
| Weighted average by Cap. | +2.25% | +2.98% | +51.27% | +97.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.6B 15.77B 14.55B 13.16B 24.62B 1,676B 25.01B 174B 69.24B 877B 66.07B 64.66B 2,779B | 18.59B 16.65B 15.36B 13.9B 25.99B 1,770B 26.41B 183B 73.1B 926B 69.75B 68.27B 2,934B |
| Net income | 5.41B 4.85B 4.47B 4.05B 7.57B 516B 7.69B 53.38B 21.3B 270B 20.32B 19.89B 855B | 5.68B 5.08B 4.69B 4.24B 7.94B 540B 8.06B 55.95B 22.32B 283B 21.3B 20.85B 896B |
| Net Debt | -7.6B -6.81B -6.28B -5.69B -10.63B -724B -10.8B -74.96B -29.9B -379B -28.53B -27.93B -1,200B | -10.97B -9.82B -9.06B -8.2B -15.34B -1,044B -15.58B -108B -43.14B -547B -41.16B -40.29B -1,731B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-30 | $914.04 | +11.64% | 1,101,180 |
| 26-10-29 | $818.77 | +0.68% | 789,303 |
| 26-10-28 | $813.27 | -0.35% | 536,498 |
| 26-10-27 | $816.10 | +1.04% | 726,151 |
| 26-10-26 | $807.67 | +0.33% | 423,958 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
